Ventyx reports positive outcomes from trial of VTX3232 for Parkinson's

Phase 3 trial of prasinezumab in early-stage Parkinson's planned

Roche said it will launch a Phase 3 trial testing prasinezumab, an anti-alpha-synuclein antibody, as a potential treatment for early-stage Parkinson’s disease. The decision follows data from two Phase 2 trials showing prasinezumab had potential clinical efficacy at slowing motor symptom progression and reducing motor complications as an add-on to standard treatments. Roche didn’t provide details about its plans for a Phase 3 trial. “We are encou…

Ventyx reports positive outcomes from trial of VTX3232 for Parkinson's

Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's.The post Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s appeared first on Clinical Trials Arena.